References
- DeVane CL. Pharmacokinetics, drug interactions, and tolerability of valproate. Psychopharmacol Bull 2003; 37 (Suppl 2) 25–42
- Dutta S, Reed RC. Distinct absorption characteristics of oral formulations of valproic acid/divalproex available in the United States. Epilepsy Res 2007; 73:275–83
- Dutta S, Reed RC, Cavanaugh JH. Absolute bioavailability and absorption characteristics of divalproex sodium extended-release tablets in healthy volunteers. J Clin Pharmacol 2004; 44:737–42
- Chun AH, Hoffman DJ, Friedmann N, . Bioavailability of valproic acid under fasting/nonfasting regimens. J Clin Pharmacol 1980; 20:30–6
- Gugler R, von Unruh GE. Clinical pharmacokinetics of valproic acid. Clin Pharmacokinet 1980; 5:67–83
- Zaccara G, Messori A, Moroni F. Clinical pharmacokinetics of valproic acid – 1988. Clin Pharmacokinet 1988; 15:367–89
- Battino D, Estienne M, Avanzini G. Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part I: phenobarbital, primidone, valproic acid, ethosuximide and mesuximide. Clin Pharmacokinet 1995; 29:257–86
- Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs 2002; 16:695–714
- Keck Jr PE, McElroy SL, Tugrul KC, . Valproate oral loading in the treatment of acute mania. J Clin Psychiatry 1993; 54:305–8
- Wilder BJ, Karas BJ, Penry JK, . Gastrointestinal tolerance of divalproex sodium. Neurology 1983; 33:808–11
- Banner Pharmacaps Inc. Data on File: High PointNC: Notebook RD6682, 82
- Depakote Tablets (prescribing information)North Chicago, IL, USA: Abbott Laboratories, 2007
- Depakene (prescribing information)North Chicago, IL, USA: Abbott Laboratories, 2006
- Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products – general considerations, 2003
- Banner Pharmacaps Inc. Data on File. PRACS Study R04–1341High Point, NC
- Banner Pharmacaps I. Data on File. PRACS Study R05–0007High Point, NC
- Diletti E, Hauschke D, Steinijans VW. Sample size determination: extended tables for the multiplicative model and bioequivalence ranges of 0.9 to 1.11 and 0.7 to 1.43. Int J Clin Pharmacol Ther Toxicol 1992; 30:287–290
- Diletti E, Hauschke D, Steinijans VW. Sample size determination for bioequivalence assessment by means of confidence intervals. Int J Clin Pharmacol Ther Toxicol 1991; 29:1–8
- Jones III WJ, Francis JJ. Softgels: consumer perceptions and market impact relative to other oral dosage forms. Adv Ther 2000; 17:213–221